Moderate-to-severe mitral regurgitation (MR) is the most common valvular heart disease in the United States, and affects more than 3 million U.S. residents with an additional 250,000 diagnoses annually. Transmural Systems is developing a fully catheter-based cerclage device to treat secondary mitral regurgitation. Using interventional techinques, a pathway is established through the coronary sinus, across the interventricular septum, into the right ventricular inflow tract and back into the right atrium. An annuloplasty-like procedure can be accomplished with circumferential tension to reduce annular dimensions.
Transmural Systems is currently in an Early Feasibility clinical trial in the U.S. with a purpose-built closure device for transcaval access to the abdominal aorta. Transcaval access is a catheter-based technique that enables non-surgical introduction of large bore devices, such as transcatheter heart valves, into the abdominal aorta.
Transmural Systems is developing a minimally invasive transcatheter device for children with congenital heart disease. This non-surgical therapy offers an alternative to the Norwood, Bi-directional Glenn and Fontan procedures limiting the burden of surgery for infants and substantially reducing healthcare costs. We have an ongoing commitment to pediatric and orphan applications through a longstanding relationship with NHLBI Lederman lab and Rady Children's Hospital (San Diego).